Skip to main content



Clinical courses

  • FDA Authorizes Second Booster Dose of Two COVID-19 Vaccines for Older and Immunocompromised Individuals

    The U.S. Food and Drug Administration authorized a second booster dose of either the Pfizer-BioNTech or the Moderna COVID-19 vaccines for older people and certain immunocompromised individuals. The FDA previously authorized a single booster dose for certain immunocompromised individuals following completion of a three-dose primary vaccination series. This action will now make a second booster dose of these vaccines available to other populations at higher risk for severe disease, hospitalization and death.

  • Natural COVID-19 antibodies lasts seven months for children : Study

    Children previously infected with COVID-19 develop natural circulating antibodies that last for at least seven months, according to a new study led by researchers at UTHealth Houston.

    The study was published today in Pediatrics.
    Researchers examined data from 218 children across the state of Texas between the ages of 5 and 19 who were enrolled in the Texas CARES survey, which began in October of 2020 with the goal of assessing COVID-19 antibody status over time among a population of adults and children in Texas.

  • Granules India receives license to market Paxlovid of Pfizer

    Granules India ltd has received a license from Medicines Patent Pool (MPP) to manufacture and market generic versions of Pfizer’s oral treatment nirmatrelvir which will be copackaged with ritonavir for treatment of COVID-19. The licenses are applicable for both active pharmaceutical ingredients (API) and finished products, in tablet form, of nirmatrelvir; ritonavir.

  • More Than Half of Physicians Have Been Asked By Patients for an Unapproved COVID-19 Treatment

    A new survey from Sermo, a physician-first online community and leader in global HCP insights, found that physicians are facing a challenging onslaught of COVID-19 vaccine and treatment misinformation as reported by 3,600+ doctors around the world.

  • New tactics for COVID-19 prophylaxis

    The ongoing SARS-CoV-2 pandemic has caused an imminent urge for both antiviral therapeutical drugs and vaccines. While the development of vaccines was accomplished in a remarkably short timeframe, the identification of direct antiviral treatments has progressed comparatively slowly. In the light of the further risk of pandemics in the future, however, there remains need for direct antiviral drugs and treatments. Moreover, emerging immune-evasive, I.e. camouflaged from the immune system, SARS-CoV-2 variants are of concern.

  • Novel Antiviral Drug Combinations Demonstrate COVID-19 Therapeutic Potential

    Researchers from Columbia Engineering, Fiocruz’s Center for Technological Development in Health and the Oswaldo Cruz Institute in Brazil, Memorial Sloan Kettering Cancer Center, and Rockefeller University recently reported that, by combining inhibitors of polymerases and exonucleases enzymes that allow SARS-CoV-2 to reproduce--they were able to reduce SARS-CoV-2 replication 10 times more than when using just the polymerase inhibitors.

  • Zymergen Advances Molecules for Prominent Malaria and COVID-19 Drug Targets for Further Testing

    Biotechnology company Zymergen is pleased to announce early results from its work on infectious disease, discovering hundreds of potential novel hits against malaria, tuberculosis, and COVID-19 targets. Hits for PfAPP, a critical target in the treatment of malaria, are now being advanced for validation, with hits for an emerging COVID-19 target, PLpro, expected to follow.

  • COVIFENZ Plant based COVID-19 Vaccine approved by Health Canada

    Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline announced that Health Canada has granted approval for COVIFENZ, COVID-19 vaccine, (plant-based virus-like particles [VLP], recombinant, adjuvanted). This vaccine is indicated for active immunization to prevent coronavirus disease 2019 (COVID‑19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) in individuals 18 to 64 years of age.

  • Repurposing FDA-approved drugs may help combat COVID-19

    Several FDA-approved drugs including for type 2 diabetes, hepatitis C and HIV significantly reduce the ability of the Delta variant of SARS-CoV-2 to replicate in human cells, according to new research led by scientists at Penn State. Specifically, the team found that these drugs inhibit certain viral enzymes, called proteases, that are essential for SARS-CoV-2 replication in infected human cells.

  • Indian made medicinal products illegally imported in Switzerland

    A large number of Indian made medicinal products illegally imported in Switzerland were seized by Swissmedic and the Federal Office for Customs and Border Security. These contained COVID-19 medicines like ivermectin, hydroxychloroquine or antibiotics and erectile stimulants from India.

    Swiss government agency along with customs had secured 9,421 packages containing illegally imported medicinal products during 2021. This is a significant increase on the previous year, when there were 6,733 such packages.

Subscribe to COVID-19